Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents

European Journal of Haematology

Volumn 92, Issue 4, 2014, Pages 308-312

  Zagouri, Flora ^a   Kastritis, Efstathios ^a   Symeonidis, Argiris S ^b   Giannakoulas, Nikolaos ^c   Katodritou, Eirini ^d   Delimpasi, Sosana ^e   Repousis, Panagiotis ^f   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d THEAGENIO CANCER HOSPITAL   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

Author keywords

Bence Jones proteinuria; IgD myeloma; Lambda light chain; Novel agents; Prognosis

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; IMMUNOGLOBULIN D; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOGLOBULIN D MULTIPLE MYELOMA; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIGHT CHAIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; VERY ELDERLY; YOUNG ADULT; BLOOD; EPIDEMIOLOGY; FACTUAL DATABASE; GREECE; INCIDENCE; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; FEMALE; GREECE; HUMANS; IMMUNOGLOBULIN D; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 84896544707     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12255     Document Type: Article

References (22)

1. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med 1975;135:87-93.
2. Fibbe WE, Jansen J. Prognostic factors in IgD myeloma: a study of 21 cases. Scand J Haematol 1984;33:471-5.
3. Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12:2398-404.
4. Sinclair D. IgD myeloma: clinical, biological and laboratory features. Clin Lab 2002;48:617-22.
5. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 1991;47:262-7.
6. Pisani F, Petrucci MT, Giannarelli D, et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res 2012;31:17.
7. Dimopoulos MA, Terpos E. Advances in the treatment of multiple myeloma. Eur J Cancer 2011;47 (Suppl 3):S306-8.
8. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749-60.
9. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
10. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086-93.
11. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69.
12. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
13. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
14. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31:2347-57.
15. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
17. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
18. Reece DE, Vesole DH, Shrestha S, et al. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk 2010;10:458-63.
19. Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol 2011;22:411-6.
20. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
21. An G, Xu Y, Shi L, Zou D, Deng S, Sui W, Xie Z, Hao M, Chang H, Qiu L. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 2013;37:1251-7.
22. Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D. IgD multiple myeloma - a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol 2005;84:115-7.